Current Report Filing (8-k)
June 16 2021 - 8:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
June 15, 2021
Date of Report
(Date of earliest event reported)
BOQI international
medical inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-50155
|
|
02-0563302
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Room 3601, Building A, Harbour View Place, No. 2 Wuwu Road,
Zhongshan District, Dalian, Liaoning Province, P. R. China, 116000
|
(Address of principal executive offices and zip code)
|
(86) 0411 8220 9211
|
(Registrant’s telephone number, including area code)
|
Not Applicable
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
|
BIMI
|
|
NASDAQ Stock Market
|
Item 8.01 Other Events.
Following
the Annual Meeting of Shareholders held on June 15, 2021, the Registrant’s Board of Directors met and appointed the following independent
directors to serve as members of the audit, nominating and compensation committees.
Committee
|
Chair
|
Members
|
Audit Committee
|
Mia Kuang Ching
|
Jianxin (Jason) Wang & Fengsheng Tan
|
Nominating Committee
|
Ju Li
|
Mia Kuang Ching & Jianxin (Jason) Wang
|
Compensation Committee
|
Fengsheng Tan
|
Ju Li & Jianxin (Jason) Wang
|
The Board of Directors also approved, effective June
15, 2021, that each independent director will be paid $24,000 per annum for their service as a director of the Company.
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: June 16, 2021
|
BOQI International Medical Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Tiewei Song
|
|
|
Tiewei Song
|
|
|
Chief Executive Officer
|
3
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Apr 2023 to Apr 2024